273 related articles for article (PubMed ID: 29282221)
1. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.
Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK
Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.
Pedron S; Hanselman JS; Schroeder MA; Sarkaria JN; Harley BAC
Adv Healthc Mater; 2017 Nov; 6(21):. PubMed ID: 28766870
[TBL] [Abstract][Full Text] [Related]
3. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels.
Wang C; Tong X; Yang F
Mol Pharm; 2014 Jul; 11(7):2115-25. PubMed ID: 24712441
[TBL] [Abstract][Full Text] [Related]
4. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
5. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
7. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
8. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
9. Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells.
Wang K; Kievit FM; Erickson AE; Silber JR; Ellenbogen RG; Zhang M
Adv Healthc Mater; 2016 Dec; 5(24):3173-3181. PubMed ID: 27805789
[TBL] [Abstract][Full Text] [Related]
10. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
11. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
13. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
14. Effect of matrix metalloproteinase-mediated matrix degradation on glioblastoma cell behavior in 3D PEG-based hydrogels.
Wang C; Tong X; Jiang X; Yang F
J Biomed Mater Res A; 2017 Mar; 105(3):770-778. PubMed ID: 27770562
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma mechanobiology at multiple length scales.
Kondapaneni RV; Gurung SK; Nakod PS; Goodarzi K; Yakati V; Lenart NA; Rao SS
Biomater Adv; 2024 Jun; 160():213860. PubMed ID: 38640876
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.
Jandial R; Neman J; Lim PP; Tamae D; Kowolik CM; Wuenschell GE; Shuck SC; Ciminera AK; De Jesus LR; Ouyang C; Chen MY; Termini J
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385725
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.
Pencheva N; de Gooijer MC; Vis DJ; Wessels LFA; Würdinger T; van Tellingen O; Bernards R
Cell Rep; 2017 Jul; 20(1):48-60. PubMed ID: 28683323
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media.
García-Romero N; González-Tejedo C; Carrión-Navarro J; Esteban-Rubio S; Rackov G; Rodríguez-Fanjul V; Oliver-De La Cruz J; Prat-Acín R; Peris-Celda M; Blesa D; Ramírez-Jiménez L; Sánchez-Gómez P; Perona R; Escobedo-Lucea C; Belda-Iniesta C; Ayuso-Sacido A
Oncotarget; 2016 Oct; 7(40):65888-65901. PubMed ID: 27589567
[TBL] [Abstract][Full Text] [Related]
20. Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.
Lindemann C; Marschall V; Weigert A; Klingebiel T; Fulda S
Neoplasia; 2015 Jun; 17(6):481-9. PubMed ID: 26152356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
